SCHEMBL311542

SCHEMBL311542

O=c1cc(-c2ccc(O)cc2)[nH]c2ccc(O)c(O)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.42
MEN1 O00255 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
PDE10A Q9Y233 2/20 0.41
TERT O14746 1/20 0.39
CDC7 O00311 1/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
SLCO2B1 O94956 1/20 0.39
NSD2 O96028 1/20 0.39
CYP1A1 P04798 1/20 0.39
FBP1 P09467 1/20 0.39
AMY1A P0DUB6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL340804 0.88 CTSV (0.52) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL312037 0.81 HPGD (0.50) KMT2AMEN1RAB9AKDM4EALDH1A1
SCHEMBL311728 0.79 ESR1 (0.49) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL313992 0.79 SMN1; SMN2 (0.43) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL340806 0.79 ALDH1A1 (0.60) KMT2AMEN1KDM4EALDH1A1HPGD
SCHEMBL312155 0.78 KMT2A (0.42) KMT2AMEN1NPC1KDM4EALDH1A1
SCHEMBL311903 0.76 CTSV (0.49) KMT2ARAB9AKDM4EALDH1A1HPGD
SCHEMBL312000 0.76 HPGD (0.61) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL312031 0.75 TERT (0.49) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL31552890 0.74 KDM4E (0.51) KMT2AMEN1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 KMT2A 2842/4885MEN1 4653/4885NPC1 26/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 KMT2A 2842/4885MEN1 4653/4885NPC1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.